Timing of postoperative radiation therapy and survival in resected salivary gland cancers: Long-term results from a single institution.
Head and neck cancer
Post-operative radiation therapy
Quality of care
Salivary gland cancer
Journal
Oral oncology
ISSN: 1879-0593
Titre abrégé: Oral Oncol
Pays: England
ID NLM: 9709118
Informations de publication
Date de publication:
12 2021
12 2021
Historique:
received:
22
07
2021
revised:
27
10
2021
accepted:
09
11
2021
pubmed:
22
11
2021
medline:
11
3
2022
entrez:
21
11
2021
Statut:
ppublish
Résumé
Timely administration of postoperative radiation therapy (PORT) impacts oncologic outcomes in resected squamous cell carcinomas of the head and neck. Salivary gland cancers (SGCs) are uncommon, and timing of PORT has not been extensively explored. We aimed to determine if the interval between surgery and PORT impacts outcomes in SGCs. This is a retrospective study of patients with SGCs who underwent curative intent surgical resection followed by adjuvant PORT. Locoregional recurrence free survival (LRFS), disease free survival (DFS), and overall survival (OS) were estimated using the Kaplan Meier method. A multivariate analysis explored the association between demographics, tumor characteristics, and PORT timing with oncologic outcomes using a stepwise Cox proportional hazards model. 180 eligible patients were identified. The median time to PORT start was 61 (range 8-121) days. 169 (93.5%) of patients received neutron radiation. With a median follow up of 8.2 years in surviving patients, the 10-year OS and LRFS estimates were 61% and 53%. In a multivariate analysis, nodal involvement, histologic grade, and age at diagnosis were associated with OS, while nodal involvement, tumor size, and age at diagnosis were associated with LRFS and DFS. Time to PORT start or completion was not statistically associated with survival outcomes. SGC patients who underwent surgery in our tertiary institution received PORT within a median of 61 days after surgery. With long term follow up, PORT timing in this retrospective series was not associated with worse oncologic outcomes, and support timely administration of PORT.
Identifiants
pubmed: 34801976
pii: S1368-8375(21)00733-8
doi: 10.1016/j.oraloncology.2021.105626
pmc: PMC8671342
mid: NIHMS1758246
pii:
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
105626Subventions
Organisme : NCI NIH HHS
ID : T32 CA009515
Pays : United States
Informations de copyright
Copyright © 2021 Elsevier Ltd. All rights reserved.
Références
Radiother Oncol. 1988 Jun;12(2):105-11
pubmed: 3406455
Anticancer Res. 2017 Sep;37(9):5019-5025
pubmed: 28870928
Cancer. 2019 Oct 1;125(19):3354-3366
pubmed: 31174233
Head Neck. 1999 Jul;21(4):297-309
pubmed: 10376748
Int J Radiat Oncol Biol Phys. 1993 Sep 30;27(2):235-40
pubmed: 8407397
Cancer. 1999 May 15;85(10):2255-64
pubmed: 10326706
Cancer. 2017 Dec 15;123(24):4841-4850
pubmed: 28841234
J Clin Oncol. 2003 Feb 1;21(3):555-63
pubmed: 12560449
Cancer. 2018 Aug 1;124(15):3154-3162
pubmed: 29742280
Oral Oncol. 2016 Mar;54:75-80
pubmed: 26723908
J Clin Oncol. 2021 Jun 10;39(17):1909-1941
pubmed: 33900808
Crit Rev Oncol Hematol. 2010 May;74(2):134-48
pubmed: 19939701
Anticancer Res. 2000 Sep-Oct;20(5C):3743-9
pubmed: 11268448
Head Neck Surg. 1986 Jan-Feb;8(3):177-84
pubmed: 3744850
Br Med J. 1975 Jun 21;2(5972):653-6
pubmed: 1095114
Laryngoscope. 2014 Jan;124(1):172-8
pubmed: 23754708